Drug Profile


Alternative Names: S-2367

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Shionogi
  • Class Amides; Cyclohexanes; Obesity therapies; Pyridines; Small molecules; Sulfonamides
  • Mechanism of Action Neuropeptide Y5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 01 Aug 2013 Discontinued - Phase-II for Obesity in Japan (PO)
  • 17 Feb 2010 Phase-II clinical trials in Obesity in Japan (PO)
  • 17 Feb 2009 Efficacy and adverse events data from two phase II trials in Type 2 diabetes mellitus released by Shinogi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top